AU2003251437A1 - Antitumor compound and therapeutic uses thereof - Google Patents

Antitumor compound and therapeutic uses thereof

Info

Publication number
AU2003251437A1
AU2003251437A1 AU2003251437A AU2003251437A AU2003251437A1 AU 2003251437 A1 AU2003251437 A1 AU 2003251437A1 AU 2003251437 A AU2003251437 A AU 2003251437A AU 2003251437 A AU2003251437 A AU 2003251437A AU 2003251437 A1 AU2003251437 A1 AU 2003251437A1
Authority
AU
Australia
Prior art keywords
therapeutic uses
antitumor compound
fgf
men2
arylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251437A
Other languages
English (en)
Other versions
AU2003251437A8 (en
Inventor
Giuliana Cassinelli
Giuditta Cuccuru
Cinzia Lanzi
Ernesto Menta
Marco Alessandro Pierotti
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Cell Therapeutics Europe SRL
Original Assignee
Novuspharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma SpA filed Critical Novuspharma SpA
Publication of AU2003251437A8 publication Critical patent/AU2003251437A8/xx
Publication of AU2003251437A1 publication Critical patent/AU2003251437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2003251437A 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof Abandoned AU2003251437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI02A001620 2002-07-23
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale
PCT/EP2003/007963 WO2004009083A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2003251437A8 AU2003251437A8 (en) 2004-02-09
AU2003251437A1 true AU2003251437A1 (en) 2004-02-09

Family

ID=30130912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251437A Abandoned AU2003251437A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof

Country Status (12)

Country Link
US (2) US20060258731A1 (it)
EP (1) EP1534271B1 (it)
JP (1) JP2005537277A (it)
CN (1) CN1668298A (it)
AT (1) ATE337001T1 (it)
AU (1) AU2003251437A1 (it)
CA (1) CA2493202A1 (it)
DE (1) DE60307856T2 (it)
ES (1) ES2271649T3 (it)
IT (1) ITMI20021620A1 (it)
MX (1) MXPA05000781A (it)
WO (1) WO2004009083A1 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
WO2006119148A2 (en) * 2005-04-29 2006-11-09 The Ohio State University Research Foundation Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
BRPI0716555A2 (pt) * 2006-09-07 2013-09-24 Astrazeneca Ab mÉtodos para prever a probabilidade de que um paciente É um candidato para tratamento com uma droga de ret responderÁ ao citado tratamento, e para tratar um paciente, iniciador direto mutante de arms, e, kit diagnàstico
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3699181T3 (pl) 2014-11-16 2023-05-22 Array Biopharma, Inc. Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
MX2018000577A (es) 2015-07-16 2018-09-05 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
SG11201803438XA (en) 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
KR20180129911A (ko) 2016-04-04 2018-12-05 록쏘 온콜로지, 인코포레이티드 소아암을 치료하는 방법
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの調製
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
CA2493202A1 (en) 2004-01-29
EP1534271A1 (en) 2005-06-01
JP2005537277A (ja) 2005-12-08
US20060258731A1 (en) 2006-11-16
DE60307856T2 (de) 2007-04-12
MXPA05000781A (es) 2005-09-21
AU2003251437A8 (en) 2004-02-09
ITMI20021620A1 (it) 2004-01-23
EP1534271B1 (en) 2006-08-23
WO2004009083A8 (en) 2005-02-03
WO2004009083A1 (en) 2004-01-29
DE60307856D1 (de) 2006-10-05
ATE337001T1 (de) 2006-09-15
ES2271649T3 (es) 2007-04-16
US20090130229A1 (en) 2009-05-21
CN1668298A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
AU2003251437A1 (en) Antitumor compound and therapeutic uses thereof
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003232882A1 (en) Prostacyclin derivatives for treating cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AUPS054702A0 (en) Cancer therapy
AU2003224654A1 (en) Photodynamic therapy for pre-melanomas
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2003275126A1 (en) Hemiasterlin derivatives for treating resistant tumors
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
AU2003290592A1 (en) Antitumor benzoylsulfonamides
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2003233733A1 (en) Compositions for cancer therapy saponins or sapogenins
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002241720A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003251595A1 (en) Enhancing treatment of mdr cancer with adenosine a3 antagonists
AU2003283339A1 (en) Cancer therapy determination

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 11, PAGE(S) 3029 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME NOVUSPHARMA S.P.A., APPLICATION NO. 2003251437, UNDER INID (71) CORRECT THE NAME TO READ CELL THERAPEUTICS EUROPE S.R.L.; INSTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI